TSY-110 (ado-trastuzumab emtansine biosimilar) / EirGenix, Formosa Pharmaceuticals - LARVOL DELTA

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers (Yahoo Finance) - "TSY-110 is a biosimilar candidate referencing Roche's antibody-drug conjugate (ADC) Kadcyla® (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer."

New trial • HER2 Positive Breast Cancer

"New Counter Stocks" Taishin Pharmaceutical starts bidding today and will be listed on August 9 [Google translation] (China Times) - "Taishin Pharmaceutical has a high-threshold special biosimilar drug research and development project TSY-0110. TSY-0110 is a research and development project using Roche's Antibody Drug Conjugate (ADC) blockbuster drug Kadcyla (Taiwanese drug name He Aining), which has a global sales volume of US$2 billion, as a control drug. The drug is based on Trastuzumab The antibody (drug name Herceptin, He Aiping) combined with the small molecule drug Emtansine is used for further treatment of HER2-positive early breast cancer and metastatic breast cancer....TSY-0110 targets Europe and the United States and will submit an EU clinical trial application this year, followed by Phase I clinical trials."

New P1 trial • Sales • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Taishin drug will be launched in August; eye drug sales are expected to reach an inflection point in 2026 [Google translation] (LINE TODAY) - "Taishin Pharmaceutical also combines the advantages of Taishin Group to develop ADC drugs. It is currently targeting the HER2-positive blockbuster drug Kadcyla biosimilar market. TSY-0110 in the product line is a combination of Taishin and Taishin's antibodies, small molecule drugs and Linking other key development and production capabilities, it aims to launch phase I clinical trials in the EU this year. Before the launch of global phase III clinical trials in 2026, it will seek appropriate licensing partners and ultimately strive to become the world's first biosimilar drug of Kadcyla."

New P1 trial • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor